Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

AstraZeneca: SocGen says 'sell' after predicting less than brilliant outlook for Brilinta

SocGen has repeated its ‘sell’ recommendation and £26.75 share price target for pharma giant AstraZeneca. Its negativity is based around what it expects to be the less-than-brilliant performance of heart and stroke drug Brilinta. It predicts other new products such as Onglyza and Bydureon (both for diabetes) will sell at a faster pace than most analysts are currently...
AstraZeneca: SocGen says 'sell' after predicting less than brilliant outlook for Brilinta

SoGen has repeated its ‘sell’ recommendation and £26.75 share price target for pharma giant AstraZeneca (LON:AZN).

Its negativity is based around what it expects to be the less-than-brilliant performance of heart and stroke drug Brilinta.

It predicts other new products such as Onglyza and Bydureon (both for diabetes) will sell at a faster pace than most analysts are currently projecting.

However, it sees challenges for Brilinta: “Our forecasts for sales are significantly below consensus because we see multiple hurdles to its use in the US, such as the negative US data from the PLATO study, which deters doctors from prescribing it, an unhelpful twice daily dosing regimen, and an interaction with statins (which is absent in competitors clopidogrel and Effient).”

At midday the shares were changing hands for £30.67, down 9.5p on the day.

 



Register here to be notified of future AZN Company articles
View full AZN profile

AstraZeneca Timeline

Related Articles

drug resistant infections such as E. coli and Pseudomonas
Tue
In vivo testing confirmed that Redx’s novel compounds were highly effective against certain drug resistant strains of bacteria.
Magnified view of cancer cells
July 28 2016
ANGLE's Parsortix blood screening system could replace the traditional biopsy in the diagnosis of breast cancer. Proactive takes a look at how it works and the potential it holds to change the way cancer is diagnosed.
Blood test
Tue
The group has ambitions to strengthen its transatlantic focus through organic and strategic growth

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.